NCT04643405 2026-01-08
APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma
Ascentage Pharma Group Inc.
Phase 1/2 Terminated
Clinical Trials
99 trialsNCT06199466 2025-12-08
A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT00529113 2025-05-29
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
Biogen
Phase 1 Terminated
NCT05389462 2025-05-22
A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors
ADC Therapeutics S.A.
Phase 1 Terminated
NCT02047500 2025-05-11
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
ImmunoGenesis
Phase 1 Terminated
NCT01834235 2025-05-07
QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer
Precision Biologics, Inc
Phase 1/2 Terminated
NCT05494866 2025-03-25
IntenSify
German Cancer Research Center
Phase 1 Terminated
NCT03520790 2025-03-21
Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT02672917 2025-01-28
Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies
BioNTech SE
Phase 1 Terminated
NCT02671890 2025-01-07
Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer
Mayo Clinic
Phase 1 Terminated
NCT01318642 2024-11-08
Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas
NantBioScience, Inc.
Phase 2 Terminated
NCT03512756 2024-11-06
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer
Tyme, Inc
Phase 2/3 Terminated
NCT04683939 2024-10-02
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
BioNTech SE
Phase 1/2 Terminated
NCT03848182 2024-04-18
Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer
Albert Einstein College of Medicine
Phase 2 Terminated
NCT03519308 2024-03-15
A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
Abramson Cancer Center at Penn Medicine
Phase EARLY_PHASE1 Terminated
NCT04046887 2024-01-05
Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)
Indiana University
Phase 1 Terminated
NCT05193604 2023-12-08
A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Terminated
NCT01897454 2023-12-05
Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer
Albert Einstein College of Medicine
Phase 2 Terminated
NCT03649321 2023-11-09
Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Terminated
NCT00625586 2023-11-03
Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
MacroGenics
Phase 2 Terminated
NCT03714555 2023-10-18
Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine
HonorHealth Research Institute
Phase 2 Terminated
NCT01461915 2022-06-06
PGPC1
Jazz Pharmaceuticals
Phase 2 Terminated
NCT02514031 2022-06-03
ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer
University of Texas Southwestern Medical Center
Phase 1 Terminated
NCT04131192 2022-05-06
Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer
Sunshine Lake Pharma Co., Ltd.
Phase 1 Terminated
NCT01198522 2022-04-15
Combination Therapy of L19IL2 and Gemcitabine in Advanced Pancreatic Cancer Patients
Philogen S.p.A.
Phase 1 Terminated
NCT00447122 2022-03-08
BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer
Brown University
Phase 1 Terminated
NCT01956812 2021-08-16
PANCRIT®-1
Gilead Sciences
Phase 3 Terminated
NCT01683422 2021-08-10
Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer
Loma Linda University
Phase NA Terminated
NCT03451773 2021-06-16
M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02608229 2021-04-21
BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Washington University School of Medicine
Phase 1 Terminated
NCT01938716 2020-11-05
Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy
M.D. Anderson Cancer Center
Phase NA Terminated
NCT00429858 2020-09-18
Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer
University of California, San Francisco
Phase 2 Terminated
NCT01836432 2020-05-28
PILLAR
Lumos Pharma
Phase 3 Terminated
NCT02405585 2020-05-28
Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer
Lumos Pharma
Phase 2 Terminated
NCT01240304 2019-12-10
A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemo With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas
University of Arkansas
Phase 2 Terminated
NCT02267707 2019-11-01
Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia
Celgene
Phase 1 Terminated
NCT02570711 2019-08-28
Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer
Acerta Pharma BV
Phase 2 Terminated
NCT02707328 2019-07-30
Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)
The Cooper Health System
Phase 1 Terminated
NCT01739439 2019-07-29
Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery
Fox Chase Cancer Center
Phase 1 Terminated
NCT01314027 2019-07-25
Adjuvant Versus Neoadjuvant Plus Adjuvant Chemotherapy in Resectable Pancreatic Cancer
University of Zurich
Phase 3 Terminated
NCT02124369 2019-07-16
PRICKLE
Cambridge University Hospitals NHS Foundation Trust
Phase 2 Terminated
NCT01313416 2019-07-10
Gemcitabine and CT-011 for Resected Pancreatic Cancer
Augusta University
Phase 2 Terminated
NCT01276613 2019-05-02
Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the Pancreas
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Terminated
NCT02910882 2019-04-11
HALO-IST
Scripps Health
Phase 2 Terminated
NCT01025882 2019-02-05
Margin-Intense Combo Therapy in Pts w/Potentially Resectable Pancreatic Cancer
University of Texas Southwestern Medical Center
Phase 1 Terminated
NCT01632306 2019-01-15
A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer
Eli Lilly and Company
Phase 1/2 Terminated
NCT02109445 2019-01-10
Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies
Pfizer
Phase 2 Terminated
NCT01086332 2018-11-13
Evaluation of Nelfinavir and Chemoradiation for Pancreatic Cancer
University of Iowa
Phase 1 Terminated
NCT00276744 2018-10-24
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated